Curriculum Vitae
Yingjie Zhang, Ph.D.
Department of Medicinal Chemistry, School of Pharmaceutical Sciences,
Shandong University.
Young Scientist of 863 Program in Biology and Medical Technology Field.
Teaching Member of National Excellent Open Course《Drug Design》.
Editorial Board Member of Anti-Cancer Agents in Medicinal Chemistry.
44 Wenhuaxi Road, Ji’nan, Shandong, 250012, P. R. China
Tel/Fax: +086-531-88382009
E-mail: zhangyingjie@sdu.edu.cn
https://www.researchgate.net/profile/Yingjie_Zhang
Education & Research Experience:
2003.09 - 2007.06: B.S. in Pharmacy, Shandong University, Ji’nan, China
2007.09 - 2012.06: PhD. in Medicinal Chemistry, Shandong University, Ji’nan, China
2012.07 - 2013.01: Research Associate in Wenfang Xu’ Group, Shandong University, Ji’nan, China
2013.02 - 2017.03: Lecture in Department of Medicinal Chemistry, Shandong University, Ji’nan, China
2013.03 - 2015.03: Postdoc. in Pharmacology, Shandong University, Ji’nan, China
2016.03 - 2017.03: Visiting Scholar in Department of Pharmacology and Cancer Biology, Duke University, U.S.A.
2017.03 - Now: Associate Professor in Department of Medicinal Chemistry, Shandong University, Ji’nan, China
Main Research Interests:
Rational design, synthesis and biological evaluation of compounds targeting histone deacetylase (HDAC), aminopeptidase (AP) and protein kinases.
Recent Publication:
Liang, X.; Zang, J.; Li, X.; Tang, S.; Huang, M.; Geng, M.; Chou, C. J.; Li, C.; Cao, Y.; Xu, W.; Liu, H.*; Zhang, Y.* Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies. J. Med. Chem. 2019, 62 (8), 3898-3923. (Cover Paper)
Zang, J.; Liang, X.; Huang, Y.; Jia, Y.; Li, X.; Xu, W.; Chou, C. J.; Zhang, Y.* Discovery of Novel Pazopanib-based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously. J. Med. Chem. 2018, 61 (12), 5304-5322.
Zhao, C.; Zang, J.; Ding, Q.; Inks, E. S.; Xu, W.; Chou, C. J.; Zhang, Y.* Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors. Eur. J. Med. Chem. 2018, 150, 282-291. (Reported by Science Trends)
Jiang, Y.; Li. X.; Hou, J.; Huang, Y.; Wang, X.; Jia, Y.; Wang, Q.; Xu, W.; Zhang, J.*; Zhang, Y.* Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy. Eur. J. Med. Chem. 2018, 143, 334-347.
Zhang, Y.*; Yan, J.; Yao, T-P.* Discovery of a fluorescent probe with HDAC6 selective inhibition. Eur. J. Med. Chem. 2017, 141, 596-602.
Li, X.;# Zhang, Y.#*; Jiang, Y.; Wu, J.; Inks, E. S.; Chou, C. J.; Gao, S.; Hou, J.; Ding, Q.; Li, J.; Wang, X.; Huang, Y.; Xu, W. Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study. Eur. J. Med. Chem. 2017, 134, 185-206.
Ma, C.; Cao, J.; Liang, X.; Huang, Y.; Wu, P.; Li, Y.; Xu, W.; Zhang, Y.* Novel leucine ureido derivatives as aminopeptidase N inhibitors. Design, synthesis and activity evaluation. Eur. J. Med. Chem. 2016, 108, 21-27.
Jiang, Y.; Li. X.; Hou, J.; Huang, Y.; Jia, Y.; Zou, M.; Zhang, J.; Wang, X.*; Xu, W.*; Zhang, Y.* Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent. Eur. J. Med. Chem., 2016, 121, 649-657.
Duan, W.; Li, J.; Inks, E. S.; Chou, C. J.; Jia, Y.; Chu, X.; Li, X.; Xu, W.*; Zhang, Y.* Design, Synthesis and Antitumor Evaluation of Novel Histone Deacetylase (HDAC) Inhibitors Equipped with Phenylsulfonylfuroxan Module as Nitric Oxide (NO) Donor. J. Med. Chem., 2015, 58 (10), 4325-4338.
Li, X.; Hou, J.; Li, X.; Jiang, Y.; Liu, X.; Mu, W.; Jin, Y.; Zhang, Y.*; Xu, W.* Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity. Eur. J. Med. Chem. 2015, 89, 628-637.
Li, X.; Inks, E. S.; Li, X.; Hou, J.; Chou, C. J.; Zhang, J.; Jiang, Y.; Zhang, Y.*; Xu, W.* Discovery of the First N-hydroxycinnamamide-based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity. J. Med. Chem., 2014, 57 (8), 3324-3341.（Reported by SciBX and Global Medical Discovery）
Xie, Y.; Xu, D.; Huang, B.; Ma, X.; Qi, W.; Shi, F.; Liu, X.*; Zhang, Y.*; Xu, W.* Discovery of N-substituted Oseltamivir Derivatives as Potent and Selective Inhibitors of H5N1 Influenza Neuraminidase. J. Med. Chem., 2014, 57 (20), 8445-8458.
Xu, F.; Zhang, L.; Jia, Y.; Wang, X.; Li, X.; Wen, Q.; Zhang, Y.*; Xu, W.* Discovery of 4-amino-2-(thio)phenol derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: Synthesis and biological evaluation. Part II. Eur. J. Med. Chem. 2013, 69, 191-200.
Zhang, Y.; Fang, H.; Feng, J.; Jia, Y.; Wang, X.; Xu, W.* Discovery of a Tetrahydroisoquinoline-Based Hydroxamic Acid Derivative (ZYJ-34c) as Histone Deacetylase Inhibitor with Potent Oral Antitumor Activities. J. Med. Chem., 2011, 54 (15), 5532-5539.
Zhang, Y.; Feng, J.; Jia, Y.; Wang, X.; Zhang, L.; Liu, C.; Fang, H.; Xu, W.* Development of Tetrahydroisoquinoline-based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in vitro and in vivo Antitumor Activities. J. Med. Chem., 2011, 54 (8), 2823-2838.
Zhang, Y.; Feng, J.; Jia, Y.; Xu, Y.; Liu, C.; Fang, H.; Xu, W.* Design, synthesis and primary activity assay of tripeptidomimetics as histone deacetylase inhibitors with linear linker and branched cap group. Eur. J. Med. Chem. 2011, 46 (11), 5387-5397.
Projects & Fundings:
1. National High-tech R&D Program of China, 863 Program (Grant No.2014AA020523), Principal Investigator.
2. National Natural Science Foundation of China (Grant No.21302111), Principal Investigator.
3. Natural Science Foundation of Shandong Province (Grant No.ZR2018QH007), Principal Investigator.
4. China Postdoctoral Science Special Foundation (Grant No.2014T70654), Principal Investigator.
5. China Postdoctoral Science Foundation (Grant No.2013M540558), Principal Investigator.
6. Postdoctoral Innovation Project Foundation of Shandong Province (Grant No.201303090), Principal Investigator.
7. Young Scholars Program of Shandong University (Grant No.2016WLJH33), Principal Investigator.
